Focus on paroxetine

Current Medical Research and Opinion

Volumn 19, Issue 1, 2003, Pages 13-21

  Green, Ben ^a,b  

^a WARRINGTON AND HALTON HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Anxiety disorders; Depressive disorders; Obsessive compulsive disorder; Paroxetine; Post traumatic stress disorder; SSRI antidepressant

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CIMETIDINE; CLOMIPRAMINE; CLOZAPINE; DIAZEPAM; FLECAINIDE; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; LOFEPRAMINE; MONOAMINE OXIDASE INHIBITOR; NORCLOZAPINE; PAROXETINE; PHENOBARBITAL; PHENOTHIAZINE; PHENYTOIN; PINDOLOL; PROPRANOLOL; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN; WARFARIN;

ANXIETY DISORDER; ASTHENIA; BODY WEIGHT DISORDER; BREAST FEEDING; CARCINOGENICITY; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG STRUCTURE; DRUG TOLERABILITY; EJACULATION DISORDER; FERTILITY; GRIEF; HEADACHE; HUMAN; INSOMNIA; MOTOR DYSFUNCTION; MUTAGENICITY; NAUSEA; NONHUMAN; OBSESSION; ORTHOSTATIC HYPERTENSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PREMATURE EJACULATION; PSYCHOPHARMACOLOGY; REVIEW; SEIZURE; SLEEP DISORDER; SOCIAL PHOBIA; SUICIDAL BEHAVIOR; TERATOGENICITY; VERTIGO; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; DEPRESSION; DRUG INTERACTIONS; HUMANS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0037234331     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125001353     Document Type: Review

References (71)

1. Byrne MM. Meta analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta Psychiat Scand Suppl 1989;350:138-9
2. Laursen AL, Mikkelsen PL, Rasmussen S, le Fevre Honore P. Paroxetine in the treatment of depression - a randomized comparison with amitriptyline. Acta Psychiatr Scand 1985;71(3):249-55
3. Claghorn JL. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. J Clin Psychiatry 53 (Suppl):33-5, 1992 Feb
4. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8(3):189-95
5. Dunbar GC, Fuell DL. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 1992;6 (Suppl)4:81-90
6. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993;13(6 Suppl 2):18S-22S
7. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998;10(4):145-50
8. Moon CA, Vince M. Treatment of major depression in general practice: a double-blind comparison of paroxetine and lofepramine. Br J Clin Pract 1996;50(5):240-4
9. Claghorn JL, Feighner JP. A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression. J Clin Psychopharmacol 1993;13(6 Suppl 2):23S-27S
10. Christiansen PE, Behnke K, Black CH, Ohrstrom JK, Bork-Rasmussen H, Nilsson J. Paroxetine and amitriptyline in the treatment of depression in general practice. Acta Psychiatr Scand 1996;93(3):158-63
11. Montgomery SA. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. Int Clin Psychopharmacol 2001;16(3):169-78
12. Rey-Sanchez F, Gutierrez-Casares JR. Paroxetine in children with major depressive disorder: an open trial. J Am Acad Child Adolesc Psychiatry 1997;36(10):1443-7
13. Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 1992;6(Suppl 4):43-51
14. Katona CL, Hunter BN, Bray J. A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13(2):100-8
15. Kerr JS, Fairweather DB, Mahendran R, Hindmarch I. The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly. Int Clin Psychopharmacol 1992;7(2):101-8
16. Findling RL, Reed MD, Myers C, O'Riordan MA, Fiala S, Branicky L, Waldorf B, Blumer JL. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(8):952-9
17. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B, Hagino OR, Koplewicz H, Carlson GA, Clarke GN, Emslie GJ, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller EB, Winters NC, Oakes R, McCafferty JP. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 200140(7):762-72
18. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Experimentation Psychopharmacologique. Am J Psychiatry 1998;155(10):1346-51
19. Tome MB, Isaac MT, Harte R, Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12(2):81-9
20. Frank MG, Hendricks SE, Johnson DR, Wieseler JL, Burke WJ. Antidepressants augment natural killer cell activity: in vivo and in vitro. Neuropsychobiology 1999;39(1):18-24
21. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15(5):986-9
22. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279(4):287-91
23. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997;95(2):153-60
24. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155(1):36-42
25. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexibledosage trial. J Clin Psychiatry 2001;62(5):350-7
26. Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280(8):708-13
27. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Br J Psychiatry 1999;175:120-6
28. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 12001;58(10):1725-7
29. Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, Campeas R, Liebowitz MR. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 1998;18(1):10-18
30. Agid O, Shalev AY, Lerer B. Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. J Clin Psychiatry 2001;62(3):169-73
31. Zygmont M, Prigerson HG, Houck PR, Miller MD, Shear MK, Jacobs S, Reynolds CF 3rd. A post hoc comparison of paroxetine and nortriptyline for symptoms of traumatic grief. J Clin Psychiatry 1998;59(5):241-5
32. Rosenberg DR, Stewart CM, Fitzgerald KD, Tawile V, Carroll E. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1999;38(9):1180-5
33. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 2000;39(9):1096-103
34. Gilbert AR, Moore GJ, Keshavan MS, Paulson LA, Narula V, MacMaster FP, Stewart CM, Rosenberg DR. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch Gen Psychiatry 2000;57(5):449-56
35. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM, Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61(4):276-81
36. Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995;5(1):5-13
37. Ludovico GM, Corvasce A, Pagliarulo G, Cirillo-Marucco E, Marano A, Pagliarulo A. Paroxetine in the treatment of premature ejaculation. Br J Urol 1996;77(6):881-2
38. Abdel-Hamid IA, El Naggar EA, El Gilany AH. Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impotence Res 2001;13(1):41-5
39. Hisaoka K, Nishida A, Koda T, Miyata M, Zensho H, Morinobu S. Ohta M, Yamawaki S. Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochemistry 200179(1):25-34
40. Thomas DR, Nelson DR, Johnson AM. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology 1987;93(2):193-200
41. Sargent P, Williamson DJ, Pearson G, Odontiadis J, Cowen PJ. Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity. Psychopharmacology 1997132(3):296-302
42. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neuroscience 1999;19(23):10494-501
43. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996;32(4):653-8
44. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 158(6):899-905
45. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR Jr. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 2001;58(7):631-40
46. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153(3):311-20
47. Bentkover JD, Feighner JP. Cost analysis of paroxetine versus imipramine in major depression. Pharmacoeconomics 1995;8(3):223-32
48. Haddad PM, Qureshi M. Misdiagnosis of antidepressant discontinuation symptoms [Comment]. Acta Psychiatr Scand 2001;104(1):77-8
49. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90(3):288-91
50. Curran S. Effect of paroxetine on seizure length during electroconvulsive therapy. Acta Psychiatr Scand 1995;92(3):239-40
51. Hendrick V, Fukuchi A, Altshuler L, Widawski M, Wertheimer A, Brunhuber MV. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001;179:163-6
52. Ohman R, Hagg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999;60(8):519-23
53. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. Akathisia: a review and case report following paroxetine treatment. Comp Psychiatry 1996;37(2):122-4
54. Fitzgerald K, Healy D. Dystonias and dyskinesias of the jaw associated with the use of SSRIs. Hum Psychopharmacology 1995;10(3):215-19
55. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [Letter]. Am J Psychiatry 1994;151(2):289
56. Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [Letter]. J Clin Psychopharmacol 1994;14(3):206-7
57. Dominguez RA, Goodnick PJ. Adverse events after the abrupt discontinuation of paroxetine. Pharmacotherapy 1995;15(6):778-80
58. Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation [Letter]. J Clin Psychopharmacol 1995;15(5):374-5
59. Pyke RE. Paroxetine withdrawal syndrome [Letter]. Am J Psychiatry 1995;152(1):149-50
60. Strickland GM, Hough DW. Unilateral facial numbness and visual blurring associated with paroxetine discontinuation [Letter]. J Clin Psychopharmacol 2000;20(2):271-2
61. Green BH. Persistent adverse neurological effects following SSRI discontinuation (PANES). Version 2.0. Psychiatry On-Line. First version published 2000. http://www.priory.com/psych/panes.htm
62. Ashton H. Brain Systems, Disorders and Psychotropic Drugs. Oxford: Oxford University Press, 1987
63. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000;15(6):305-18
64. Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol 2001;21(3):293-7
65. Modell JG, Katholi CR, Modell JD, DePalma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997;61(4):476-87
66. Oswald I, Adam K. Effects of paroxetine on human sleep. Br J Clin Pharmacol 22(1):97-9
67. Saletu B, Frey R, Krupka M, Anderer P, Grunberger J, See WR. Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 1991;14(5):439-47
68. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology 1996;126(1):50-4
69. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1996;10(4):145-50
70. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Madia A. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. TherDrug Monit 2001;23(3):223-7
71. Spina E, Avenoso A, Salemi M, Facciola G, Scordo MG, Ancione M, Madia A. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000;33(6):213-7